<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="brief-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hematol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Hematol Rep</journal-id><journal-id journal-id-type="publisher-id">hematolrep</journal-id><journal-title-group><journal-title>Hematology Reports</journal-title></journal-title-group><issn pub-type="ppub">2038-8322</issn><issn pub-type="epub">2038-8330</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407636</article-id><article-id pub-id-type="pmc">PMC12101365</article-id>
<article-id pub-id-type="doi">10.3390/hematolrep17030026</article-id><article-id pub-id-type="publisher-id">hematolrep-17-00026</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Clinical Outcome and Molecular Profile in Patients with <italic toggle="yes">DDX41</italic> Mutation Hot-Spots</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Toumeh</surname><given-names>Nadia</given-names></name><xref rid="af1-hematolrep-17-00026" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Jabban</surname><given-names>Yazan</given-names></name><xref rid="af2-hematolrep-17-00026" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Nanaa</surname><given-names>Ahmad</given-names></name><xref rid="af3-hematolrep-17-00026" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Rong</given-names></name><xref rid="af4-hematolrep-17-00026" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Viswanatha</surname><given-names>David</given-names></name><xref rid="af4-hematolrep-17-00026" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Jevremovic</surname><given-names>Dragan</given-names></name><xref rid="af4-hematolrep-17-00026" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Foran</surname><given-names>James M.</given-names></name><xref rid="af5-hematolrep-17-00026" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Arana Yi</surname><given-names>Cecilia Y.</given-names></name><xref rid="af6-hematolrep-17-00026" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5134-7336</contrib-id><name><surname>Saliba</surname><given-names>Antoine N.</given-names></name><xref rid="af2-hematolrep-17-00026" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Hefazi Torghabeh</surname><given-names>Mehrdad</given-names></name><xref rid="af2-hematolrep-17-00026" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5841-4105</contrib-id><name><surname>Hogan</surname><given-names>William J.</given-names></name><xref rid="af2-hematolrep-17-00026" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5359-336X</contrib-id><name><surname>Shah</surname><given-names>Mithun V.</given-names></name><xref rid="af2-hematolrep-17-00026" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Mangaonkar</surname><given-names>Abhishek A.</given-names></name><xref rid="af2-hematolrep-17-00026" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Patnaik</surname><given-names>Mrinal M.</given-names></name><xref rid="af2-hematolrep-17-00026" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3609-8404</contrib-id><name><surname>Alkhateeb</surname><given-names>Hassan B.</given-names></name><xref rid="af2-hematolrep-17-00026" ref-type="aff">2</xref><xref rid="c1-hematolrep-17-00026" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0824-3715</contrib-id><name><surname>Al-Kali</surname><given-names>Aref</given-names></name><xref rid="af2-hematolrep-17-00026" ref-type="aff">2</xref><xref rid="c1-hematolrep-17-00026" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Braester</surname><given-names>Andrei</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Cumbo</surname><given-names>Cosimo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-hematolrep-17-00026"><label>1</label>Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA; <email>toumeh.nadia@mayo.edu</email></aff><aff id="af2-hematolrep-17-00026"><label>2</label>Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA; <email>jabban.yazankhaireldien@mayo.edu</email> (Y.J.); <email>saliba.antoine@mayo.edu</email> (A.N.S.); <email>hefazitorghabeh.mehrdad@mayo.edu</email> (M.H.T.); <email>hogan.william@mayo.edu</email> (W.J.H.); <email>shah.mithun@mayo.edu</email> (M.V.S.); <email>mangaonkar.abhishek@mayo.edu</email> (A.A.M.); <email>patnaik.mrinal@mayo.edu</email> (M.M.P.)</aff><aff id="af3-hematolrep-17-00026"><label>3</label>John H. Stroger, Jr. Hospital of Cook County, Chicago, MN 60612, USA; <email>ananaa2@uic.edu</email></aff><aff id="af4-hematolrep-17-00026"><label>4</label>Division of Hematopathology, Mayo Clinic, Rochester, MN 55905, USA; <email>he.rong@mayo.edu</email> (R.H.); <email>viswanatha.david@mayo.edu</email> (D.V.); <email>jevremovic.dragan@mayo.edu</email> (D.J.)</aff><aff id="af5-hematolrep-17-00026"><label>5</label>Division of Hematology &#x00026; Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA; <email>foran.james@mayo.edu</email></aff><aff id="af6-hematolrep-17-00026"><label>6</label>Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85054, USA; <email>aranayi.cecilia@mayo.edu</email></aff><author-notes><corresp id="c1-hematolrep-17-00026"><label>*</label>Correspondence: <email>alkhateeb.hassan@mayo.edu</email> (H.B.A.); <email>alkali.aref@mayo.edu</email> (A.A.-K.)</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>26</elocation-id><history><date date-type="received"><day>21</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold>&#x000a0;<italic toggle="yes">DDX41</italic>, DEAD-box RNA helicase 41 gene located on chromosome 5q25.3, is one of the most mutated genes in patients with germline predisposition to myeloid neoplasms. Germline and somatic mutations often have different locations and patterns of mutation, with some hotspots displaying diversity based on ethnicity. We aimed to explore clinical outcomes in patients with various <italic toggle="yes">DDX41</italic> hot-spot mutations. <bold>Methods</bold>: This was a retrospective study of patients at Mayo Clinic with <italic toggle="yes">DDX41</italic> mutation identified through Next Generation Sequencing (NGS) between 2018 and 2024. We completed unadjusted comparisons using continuous or categorical variables, and survival rates were assessed using the Kaplan&#x02013;Meier method and cox regression analysis. <bold>Results</bold>: Overall survival appears to be higher in those with p.M1| when compared to p.Asp140GlyFs*2 and p.Arg525His, with comparable survival between p.Arg525His and p.Asp140GlyFs*2. Among males with p.M1| who underwent bone marrow transplant, those who underwent bone marrow transplant appeared to have lower survival rates, although not statistically significant. Our study was limited by a small sample size, therefore limiting our ability to reach significance. <bold>Conclusions</bold>: Our findings suggest potential implications for clinical outcomes based on <italic toggle="yes">DDX41</italic> mutation hot-spots.</p></abstract><kwd-group><kwd><italic toggle="yes">DDX41</italic></kwd><kwd>MDS</kwd><kwd>AML</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-hematolrep-17-00026"><title>1. Introduction</title><p>The DEAD-box RNA helicase 41 (<italic toggle="yes">DDX41</italic>) gene is located on chromosome 5q35.3 and is involved in several cellular functions. As part of the RNA helicase family, this gene is thought to be involved in RNA splicing and ribosome biogenesis [<xref rid="B1-hematolrep-17-00026" ref-type="bibr">1</xref>,<xref rid="B2-hematolrep-17-00026" ref-type="bibr">2</xref>]. <italic toggle="yes">DDX41</italic> interacts with spliceosome proteins, and defects in the gene can lead to dysfunction in alternative splicing. The gene also acts as a pattern recognition receptor that detects pathogens, therefore playing a role in innate immunity [<xref rid="B2-hematolrep-17-00026" ref-type="bibr">2</xref>]. The mechanism with which mutations in the gene predispose a patient to myeloid malignancies is not completely understood; <italic toggle="yes">DDX41</italic> is one of the most commonly mutated genes in those with myeloid malignancies with germline predisposition [<xref rid="B1-hematolrep-17-00026" ref-type="bibr">1</xref>,<xref rid="B3-hematolrep-17-00026" ref-type="bibr">3</xref>]. Patients with <italic toggle="yes">DDX41</italic> mutation who go on to develop myeloid neoplasms often have a germline heterozygous mutation and acquire a somatic mutation in the second <italic toggle="yes">DDX41</italic> allele usually in the sixth decade of life. This &#x0201c;second hit&#x0201d; typically leads to development of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and there is an increased frequency of disease progression in males compared to females [<xref rid="B2-hematolrep-17-00026" ref-type="bibr">2</xref>]. Up to 80% of <italic toggle="yes">DDX41</italic> germline mutation carriers who develop MDS/AML have an additional somatic mutation of the gene [<xref rid="B4-hematolrep-17-00026" ref-type="bibr">4</xref>].</p><p>The World Health Organization (WHO) classification in 2016 recognized myeloid neoplasms with germline predisposition as separate clinical entities [<xref rid="B3-hematolrep-17-00026" ref-type="bibr">3</xref>]. As reported by Alkhateeb et al., the most common pathogenic mutation observed in a group of 33 patients with <italic toggle="yes">DDX41</italic> was M1| [<xref rid="B5-hematolrep-17-00026" ref-type="bibr">5</xref>]. In another study of 191 patients with <italic toggle="yes">DDX41</italic> mutation, other frequent <italic toggle="yes">DDX41</italic> variants were p.Arg525His and p.Asp140GlyFs*2 [<xref rid="B6-hematolrep-17-00026" ref-type="bibr">6</xref>]. The hot-spot mutation p.M1| has also been found in other studies to be more common compared to other locations in those with germline mutation [<xref rid="B7-hematolrep-17-00026" ref-type="bibr">7</xref>]. Our study investigates clinical outcomes and molecular profiles of patients with different <italic toggle="yes">DDX41</italic> mutation (m) hot-spots. Identifying patients with germline mutations such as <italic toggle="yes">DDX41</italic> carries implications for treatment options, stem cell transplant donor eligibility, and the need for genetic counseling [<xref rid="B3-hematolrep-17-00026" ref-type="bibr">3</xref>].</p></sec><sec id="sec2-hematolrep-17-00026"><title>2. Materials and Methods</title><p>We conducted a single institution retrospective study of patients at Mayo Clinic with pathogenic <italic toggle="yes">DDX41</italic> mutations, diagnosed through our next generation sequencing (NGS) between 2018 and 2024. More specifically, this was the myeloid NGS obtained either at or shortly after diagnosis. An appropriate institutional review board (IRB) approval was obtained. The data regarding mutations was recorded at the time of the patient&#x02019;s first NGS that identified a <italic toggle="yes">DDX41</italic> mutation. Myeloid neoplasms were diagnosed based on the WHO 2022 diagnostic criteria [<xref rid="B8-hematolrep-17-00026" ref-type="bibr">8</xref>]. We classified patients as having germline <italic toggle="yes">DDX41</italic> variants or somatic variants based on confirmed germline testing results, although only 32 patients in this study (47%) chose to undergo germline testing. Germline testing was performed using either peripheral blood, or buccal/skin samples. Our analysis primarily focused on differences between the most frequent <italic toggle="yes">DDX41</italic> hot-spot variants: p.M1|, p.Arg525His, and p.Asp140GlyFs*2Gly. An unadjusted comparison using continuous or categorical variables was completed, with survival rates assessed using the Kaplan&#x02013;Meier method and cox regression analysis. The median overall survival (mOS) was calculated from the time of NGS to the last follow-up or death, utilizing BlueSky Statistics V.10.3.4. Due to the limited number of cases in some variant groups, the mOS was not reached. Therefore, survival probabilities at the 12- and 24-month points were used as an alternative measure to evaluate survival outcomes. We compared our study findings with the findings published in Makishima et al. [<xref rid="B9-hematolrep-17-00026" ref-type="bibr">9</xref>].</p></sec><sec sec-type="results" id="sec3-hematolrep-17-00026"><title>3. Results</title><p>In our study, we included 68 patients who were identified to have pathogenic <italic toggle="yes">DDX41</italic> mutation on NGS. We excluded patients who had a <italic toggle="yes">DDX41</italic> mutation that was only a variant of undetermined significance (VUS). Of the 68 patients included, 30 had MDS, 23 had AML, 4 had MPN, 6 were <italic toggle="yes">DDX41</italic> carriers, and 5 carried other diagnoses: clonal cytopenia of undetermined significance (CCUS) and clonal hematopoiesis with indeterminate potential (CHIP). The majority of the patients were male (M&#x02013;F 48:20) with a median age of diagnosis of 72 years (range 30&#x02013;93). A total of 48 of the patients with <italic toggle="yes">DDX41</italic> pathogenic mutation had normal cytogenetics, and 20 (29%) of the patients underwent bone marrow transplantation. <xref rid="hematolrep-17-00026-t001" ref-type="table">Table 1</xref> includes the baseline characteristics of all 68 patients: diagnosis, median age at diagnosis, DDX41 median variant allele frequency (VAF), cytogenetics, median bone marrow blast percentage, and confirmed germline mutation (<xref rid="hematolrep-17-00026-t001" ref-type="table">Table 1</xref>). In <xref rid="hematolrep-17-00026-t002" ref-type="table">Table 2</xref>, we focus on patients with only p.M1|, p.Arg525His, and p.Asp140GlyFs*2, and describe the clinical characteristics of these patients as well as overall survival.</p><p>Mutations: Mutation hot-spots included 9 patients with p.Arg525His only, 23 p.M1| only, 8 p.Asp140GlyFs*2 only, 7 p.Arg525His with other than p.M1|, and 1 patient with p.Arg525His and p.Asp140GlyFs*2 co-mutation, 1 patient had p.M1| and p.Arg525His, and 2 patients had p.M1| hot-spot with non-p.Arg525His and p.Asp140GlyFs*2. Lastly, 17 patients had mutations in locations other than specified in this study (<xref rid="hematolrep-17-00026-f001" ref-type="fig">Figure 1</xref>A).</p><p>Characteristics: The median age of diagnosis was 72 years in p.M1|, 69 years in p.Arg525His, and 63.5 years in p.Asp140GlyFs*2 mutation groups (<italic toggle="yes">p</italic> = 0.77). Patients with p.M1|, compared to p.Arg525His and p.Asp140GlyFs*2 hot-spot mutations had higher median hemoglobin level, white count level, and bone marrow blast percentage, although this was not statistically significant (<italic toggle="yes">p</italic> = 0.68, <italic toggle="yes">p</italic> = 0.24, <italic toggle="yes">p</italic> = 0.57). Patients with p.M1| were more likely, although not statistically significant, to carry normal cytogenetics, with around 90% of patients having normal cytogenetics (<italic toggle="yes">p</italic> = 0.17). This group also had the highest proportion of male patients compared to p.Arg525His and p.Asp140GlyFs*2 (<italic toggle="yes">p</italic> = 0.56). When comparing p.M1| to p.Arg525His, those with p.M1| had a higher percentage of <italic toggle="yes">DDX41</italic> variant allele frequency (VAF) percentage (48% vs. 11%, <italic toggle="yes">p</italic> = 0.001). As for germline mutations, 6 of the 23 patients with p.M1| had confirmed germline mutation, as well as 2 of the patients with only p.Asp140GlyFs*2 mutation and 1 of the patients with only p.Arg525His mutation.</p><p>Co-mutations: When looking at co-mutation prevalence, all patients had low mean number of co-mutations (p.M1| 0.3, compared to 0.6 in p.Arg525His and 0.5 in p.Asp140GlyFs*2 (<italic toggle="yes">p</italic> = 0.63)). A total of 78% of patients with p.M1| had isolated <italic toggle="yes">DDX41</italic> mutation, compared to 56% of patients with p.Arg525His and 62% of patients with p.Asp140GlyFs*2 mutation (<italic toggle="yes">p</italic> = 0.15). The most common co-mutation in p.M1| hot-spot carriers was <italic toggle="yes">ASXL1,</italic> found in 13% of patients, while the most common co-mutation in p.Asp140GlyFs*2 was <italic toggle="yes">DNMT3A</italic>, found in 29% of patients. p.Arg525His patients had various co-mutations (<italic toggle="yes">JAK2</italic>, <italic toggle="yes">CBL</italic>, <italic toggle="yes">DNMT3A</italic>, <italic toggle="yes">SETBP1)</italic>, but none were significantly more common than the others. <xref rid="hematolrep-17-00026-f001" ref-type="fig">Figure 1</xref>B displays an overview of co-mutation prevalence in the 68 patients that we studied.</p><p>Survival: We also looked at overall survival data amongst the hot-spot mutation groups, at 12 and 24 months. At 12 and 24 months, overall survival rate was 100% and 83% in the p.M1| group, compared to 75% survival rate at 12 months and 24 months for those with p.Arg525His (<italic toggle="yes">p</italic> = 0.40, <xref rid="hematolrep-17-00026-f001" ref-type="fig">Figure 1</xref>C). The p.Asp140GlyFs*2 group had 86% and 74% survival at 12 and 24 months, respectively; again a lower survival rate than those with M1| at those time periods (<italic toggle="yes">p</italic> = 0.79, <xref rid="hematolrep-17-00026-f001" ref-type="fig">Figure 1</xref>D). At 12 and 24 months, patients with p.Asp140GlyFs*2 and p.Arg525His had comparable survival probability (<xref rid="hematolrep-17-00026-f001" ref-type="fig">Figure 1</xref>E, <italic toggle="yes">p</italic> = 0.43). Among patients with only p.M1| mutation (N = 23), four of those patients underwent bone marrow transplantation (BMT). Three of those patients had high risk MDS, and one patient had AML. Those who underwent BMT = had lower median survival compared to those who did not undergo BMT (median overall survival of 63 vs. 158 months, <italic toggle="yes">p</italic> = 0.38).</p></sec><sec sec-type="discussion" id="sec4-hematolrep-17-00026"><title>4. Discussion</title><p>Mutations in <italic toggle="yes">DDX41</italic> account for 2&#x02013;5% of patients with myeloid neoplasms, with the predominant germline mutations being frameshift, truncation, and missense [<xref rid="B1-hematolrep-17-00026" ref-type="bibr">1</xref>]. The most frequent <italic toggle="yes">DDX41</italic> germline variant in a retrospective study completed by Bataller et al., in keeping with our study, was p.M1| [<xref rid="B3-hematolrep-17-00026" ref-type="bibr">3</xref>]. As seen in our study, p.M1| demonstrates male predominance and higher likelihood of having normal cytogenetics [<xref rid="B10-hematolrep-17-00026" ref-type="bibr">10</xref>]. Patients with p.M1| in our study were also likely to have fewer co-mutations, similar to Makishima et al. [<xref rid="B9-hematolrep-17-00026" ref-type="bibr">9</xref>].</p><p>Our study also supports other findings in the multi-institutional study completed by Makishima et al. [<xref rid="B9-hematolrep-17-00026" ref-type="bibr">9</xref>]. In that study, there were 346 patients with a myeloid neoplasm and <italic toggle="yes">DDX41</italic> mutation, of which 11 patients had p.M1| only, 15 had p.Arg525His only, and 24 patients had p.Asp140GlyFs*2 only. Similar to our findings, only 2 of the 346 had p.M1| and p.Arg525His co-existing hot-spots (2% in our study). Only 13 patients (3%) in Makishima et al. had co-existing p.Arg525His and p.Asp140GlyFs*2 mutation, representing similar findings to our study (2% in our study).</p><p>Patients in Makishima et al. had a low mean number of co-mutations, with p.M1| hot-spot mutation carriers having a mean number of 0.3 (range 0&#x02013;2), compared to a mean of 0.9 (range 0&#x02013;2) in p.Arg525His and 0.5 (range 0&#x02013;3) in p.Asp140GlyFs*2 (which is similar to our study). In Makishima et al., we found that p.M1| were more likely to have isolated <italic toggle="yes">DDX41</italic>, compared to all other mutation sites (<italic toggle="yes">p</italic> = 0.01). This finding is also reported in Duployez et al., where 191 patients with <italic toggle="yes">DDX41</italic> mutation were studied and p.M1| was not significantly associated with co-mutations [<xref rid="B6-hematolrep-17-00026" ref-type="bibr">6</xref>,<xref rid="B9-hematolrep-17-00026" ref-type="bibr">9</xref>]. Patients in Makishima et al. with all other <italic toggle="yes">DDX41</italic> mutations had a mean co-mutation number of 1.1 (range 0&#x02013;10, <italic toggle="yes">p</italic> = 0.03). The most common co-mutations in p.Asp140GlyFs*2 were <italic toggle="yes">SETBP1</italic>, <italic toggle="yes">DNMT3A</italic>, and <italic toggle="yes">SRSF2</italic>. In p.Arg525His, the most common co-mutation was <italic toggle="yes">ASXL1</italic>. The patients with only p.M1| hot-spot had a variety of co-mutations including <italic toggle="yes">ASXL1</italic>, <italic toggle="yes">DNMT3A</italic>, and <italic toggle="yes">SETBP1</italic> [<xref rid="B9-hematolrep-17-00026" ref-type="bibr">9</xref>].</p><p>As for survival probability, those with p.M1| at 12 and 24 months had higher survival rates in our study, compared to p.Asp140GlyFs*2 and p.Arg525His, although not statistically significant. At 12 and 24 months, patients with p.Asp140GlyFs*2 and p.Arg525His had comparable survival probability. We also found that those with p.M1| and who underwent bone marrow transplant had lower median survival, although again not statistically significant.</p><p>Our study has several implications when it comes to taking care of patients found to have <italic toggle="yes">DDX41</italic> mutation. We believe that there is clinical utility in delineating certain hot-spot mutations present in those with <italic toggle="yes">DDX41</italic> mutation. Although our study was limited by sample size, we believe that certain hot-spot mutations may affect the patient&#x02019;s success with bone marrow transplant and their likelihood of carrying other mutations known to play a role in myeloid neoplasm. For example, recent studies have noted &#x0201c;observation&#x0201d; as an option in patients who were enriched with p.Arg525His [<xref rid="B11-hematolrep-17-00026" ref-type="bibr">11</xref>]. We hope to continue to expand on this data, allowing us to draw more significant conclusions.</p><sec><title>Study Limitations and Future Directions</title><p>We would like to mention some of the limitations of our study. First of all, our sample size was small, reflecting the need for emerging studies of the <italic toggle="yes">DDX41</italic> mutation. In addition, the retrospective nature is also inferior to that of a prospective study that analyzes patients with <italic toggle="yes">DDX41</italic> mutation. Additionally, not all of the patients in our sample underwent germline testing, therefore limiting some of the conclusions we can draw regarding the population.</p></sec></sec><sec sec-type="conclusions" id="sec5-hematolrep-17-00026"><title>5. Conclusions</title><p>The p.M1| hot-spot in the gene was significantly associated with higher VAF percentage and is more commonly seen in germline <italic toggle="yes">DDX41</italic> mutation. Co-mutation frequency differed by hot-spot mutation while p.Arg525His as a second mutation was seen mainly in cases other than p.M1|/pAsp140GlyFs*2. Overall survival appears to be higher in those with p.M1| compared to p.Arg525His and p.Asp140GlyFs*2, though small sample size limits our ability to draw significant conclusions. Additionally, those with M1| only mutation who underwent p.M1|bone marrow transplant had lower survival, although not statistically significant. Our findings suggest potential implications for clinical outcomes based on <italic toggle="yes">DDX41</italic> mutation hot-spots.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.A.-K. and N.T.; methodology, A.A.-K., Y.J. and N.T.; validation, Y.J. and N.T.; formal analysis, Y.J. and N.T.; writing&#x02014;original draft preparation, N.T. and A.A.-K.; writing&#x02014;review and editing, remaining authors; funding acquisition, A.A.-K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review of Mayo Clinic Rochester.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">NGS </td><td align="left" valign="middle" rowspan="1" colspan="1">Next Generation Sequencing </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMT </td><td align="left" valign="middle" rowspan="1" colspan="1">Bone marrow transplant</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHIP </td><td align="left" valign="middle" rowspan="1" colspan="1">Clonal hematopoiesis of indeterminate potential </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OS </td><td align="left" valign="middle" rowspan="1" colspan="1">Overall survival </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDS</td><td align="left" valign="middle" rowspan="1" colspan="1">Myelodysplastic syndrome </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AML</td><td align="left" valign="middle" rowspan="1" colspan="1">Acute Myeloid leukemia </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MPN </td><td align="left" valign="middle" rowspan="1" colspan="1">Myeloproliferative neoplasm</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CCUS</td><td align="left" valign="middle" rowspan="1" colspan="1">Clonal cytopenia of undetermined significance</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-hematolrep-17-00026"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Winstone</surname><given-names>L.</given-names></name>
<name><surname>Jung</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
</person-group><article-title>DDX41: Exploring the roles of a versatile helicase</article-title><source>Biochem. Soc. Trans.</source><year>2024</year><volume>52</volume><fpage>395</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1042/BST20230725</pub-id><pub-id pub-id-type="pmid">38348889</pub-id>
</element-citation></ref><ref id="B2-hematolrep-17-00026"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagata</surname><given-names>Y.</given-names></name>
</person-group><article-title>Molecular pathophysiology of germline mutations in acute myeloid leukemia</article-title><source>Int. J. Hematol.</source><year>2024</year><volume>120</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1007/s12185-024-03824-x</pub-id><pub-id pub-id-type="pmid">39150677</pub-id>
</element-citation></ref><ref id="B3-hematolrep-17-00026"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bataller</surname><given-names>A.</given-names></name>
<name><surname>Loghavi</surname><given-names>S.</given-names></name>
<name><surname>Gerstein</surname><given-names>Y.</given-names></name>
<name><surname>Bazinet</surname><given-names>A.</given-names></name>
<name><surname>Sasaki</surname><given-names>K.</given-names></name>
<name><surname>Chien</surname><given-names>K.S.</given-names></name>
<name><surname>Hammond</surname><given-names>D.</given-names></name>
<name><surname>Montalban-Bravo</surname><given-names>G.</given-names></name>
<name><surname>Borthakur</surname><given-names>G.</given-names></name>
<name><surname>Short</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Characteristics and clinical outcomes of patients with myeloid malignancies and <italic toggle="yes">DDX41</italic> variants</article-title><source>Am. J. Hematol.</source><year>2023</year><volume>98</volume><fpage>1780</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1002/ajh.27070</pub-id><pub-id pub-id-type="pmid">37665752</pub-id>
</element-citation></ref><ref id="B4-hematolrep-17-00026"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Ong</surname><given-names>F.</given-names></name>
<name><surname>Sasaki</surname><given-names>K.</given-names></name>
</person-group><article-title>Current Understanding of <italic toggle="yes">DDX41</italic> Mutations in Myeloid Neoplasms</article-title><source>Cancers</source><year>2023</year><volume>15</volume><elocation-id>344</elocation-id><pub-id pub-id-type="doi">10.3390/cancers15020344</pub-id><pub-id pub-id-type="pmid">36672294</pub-id>
</element-citation></ref><ref id="B5-hematolrep-17-00026"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alkhateeb</surname><given-names>H.B.</given-names></name>
<name><surname>Nanaa</surname><given-names>A.</given-names></name>
<name><surname>Viswanatha</surname><given-names>D.S.</given-names></name>
<name><surname>Foran</surname><given-names>J.M.</given-names></name>
<name><surname>Badar</surname><given-names>T.</given-names></name>
<name><surname>Sproat</surname><given-names>L.</given-names></name>
<name><surname>He</surname><given-names>R.</given-names></name>
<name><surname>Nguyen</surname><given-names>P.</given-names></name>
<name><surname>Jevremovic</surname><given-names>D.</given-names></name>
<name><surname>Salama</surname><given-names>M.E.</given-names></name>
<etal/>
</person-group><article-title>Genetic features and clinical outcomes of patients with isolated and comutated <italic toggle="yes">DDX41</italic>-mutated myeloid neoplasms</article-title><source>Blood Adv.</source><year>2022</year><volume>6</volume><fpage>528</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2021005738</pub-id><pub-id pub-id-type="pmid">34644397</pub-id>
</element-citation></ref><ref id="B6-hematolrep-17-00026"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duployez</surname><given-names>N.</given-names></name>
<name><surname>Largeaud</surname><given-names>L.</given-names></name>
<name><surname>Duchmann</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>R.</given-names></name>
<name><surname>Rieunier</surname><given-names>J.</given-names></name>
<name><surname>Lambert</surname><given-names>J.</given-names></name>
<name><surname>Bidet</surname><given-names>A.</given-names></name>
<name><surname>Larcher</surname><given-names>L.</given-names></name>
<name><surname>Lemoine</surname><given-names>J.</given-names></name>
<name><surname>Delhommeau</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Prognostic impact of <italic toggle="yes">DDX41</italic> germline mutations in intensively treated acute myeloid leukemia patients: An ALFA-FILO study</article-title><source>Blood</source><year>2022</year><volume>140</volume><fpage>756</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1182/blood.2021015328</pub-id><pub-id pub-id-type="pmid">35443031</pub-id>
</element-citation></ref><ref id="B7-hematolrep-17-00026"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quesada</surname><given-names>A.E.</given-names></name>
<name><surname>Routbort</surname><given-names>M.J.</given-names></name>
<name><surname>DiNardo</surname><given-names>C.D.</given-names></name>
<name><surname>Bueso-Ramos</surname><given-names>C.E.</given-names></name>
<name><surname>Kanagal-Shamanna</surname><given-names>R.</given-names></name>
<name><surname>Khoury</surname><given-names>J.D.</given-names></name>
<name><surname>Thakral</surname><given-names>B.</given-names></name>
<name><surname>Zuo</surname><given-names>Z.</given-names></name>
<name><surname>Yin</surname><given-names>C.C.</given-names></name>
<name><surname>Loghavi</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease</article-title><source>Am. J. Hematol.</source><year>2019</year><volume>94</volume><fpage>757</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1002/ajh.25486</pub-id><pub-id pub-id-type="pmid">30963592</pub-id>
</element-citation></ref><ref id="B8-hematolrep-17-00026"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Qin</surname><given-names>T.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Qu</surname><given-names>S.</given-names></name>
<name><surname>Pan</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Yan</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms</article-title><source>Leukemia</source><year>2022</year><volume>36</volume><fpage>2875</fpage><lpage>2882</lpage><pub-id pub-id-type="doi">10.1038/s41375-022-01718-7</pub-id><pub-id pub-id-type="pmid">36224330</pub-id>
</element-citation></ref><ref id="B9-hematolrep-17-00026"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makishima</surname><given-names>H.</given-names></name>
<name><surname>Saiki</surname><given-names>R.</given-names></name>
<name><surname>Nannya</surname><given-names>Y.</given-names></name>
<name><surname>Korotev</surname><given-names>S.C.</given-names></name>
<name><surname>Gurnari</surname><given-names>C.</given-names></name>
<name><surname>Takeda</surname><given-names>J.</given-names></name>
<name><surname>Momozawa</surname><given-names>Y.</given-names></name>
<name><surname>Best</surname><given-names>S.</given-names></name>
<name><surname>Krishnamurthy</surname><given-names>P.</given-names></name>
<name><surname>Yoshizato</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Germ line <italic toggle="yes">DDX41</italic> mutations define a unique subtype of myeloid neoplasms</article-title><source>Blood</source><year>2023</year><volume>141</volume><fpage>534</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1182/blood.2022018221</pub-id><pub-id pub-id-type="pmid">36322930</pub-id>
</element-citation></ref><ref id="B10-hematolrep-17-00026"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Badar</surname><given-names>T.</given-names></name>
<name><surname>Nanaa</surname><given-names>A.</given-names></name>
<name><surname>Foran</surname><given-names>J.M.</given-names></name>
<name><surname>Viswanatha</surname><given-names>D.</given-names></name>
<name><surname>Al-Kali</surname><given-names>A.</given-names></name>
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Finke</surname><given-names>C.</given-names></name>
<name><surname>Alkhateeb</surname><given-names>H.B.</given-names></name>
<name><surname>He</surname><given-names>R.</given-names></name>
<name><surname>Gangat</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms</article-title><source>Haematologica</source><year>2023</year><volume>108</volume><fpage>3033</fpage><lpage>3043</lpage><pub-id pub-id-type="doi">10.3324/haematol.2023.282867</pub-id><pub-id pub-id-type="pmid">37199125</pub-id>
</element-citation></ref><ref id="B11-hematolrep-17-00026"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Kali</surname><given-names>A.</given-names></name>
<name><surname>Nanaa</surname><given-names>A.</given-names></name>
<name><surname>Viswanatha</surname><given-names>D.</given-names></name>
<name><surname>He</surname><given-names>R.</given-names></name>
<name><surname>Nguyen</surname><given-names>P.</given-names></name>
<name><surname>Jevremovic</surname><given-names>D.</given-names></name>
<name><surname>Foran</surname><given-names>J.M.</given-names></name>
<name><surname>Yi</surname><given-names>C.A.</given-names></name>
<name><surname>Greipp</surname><given-names>P.T.</given-names></name>
<name><surname>Gangat</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome</article-title><source>Blood Cancer J.</source><year>2023</year><volume>13</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1038/s41408-023-00818-6</pub-id><pub-id pub-id-type="pmid">37032414</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="hematolrep-17-00026-f001"><label>Figure 1</label><caption><p>(<bold>A</bold>) Distribution of <italic toggle="yes">DDX41</italic> mutations, with those with isolated <italic toggle="yes">DDX41</italic> mutation above the gene box and co-mutated <italic toggle="yes">DDX41</italic> patients below the gene box. Black circles indicate patients without available genetic alteration information; (<bold>B</bold>) patterns of co-mutation with respective VAF among <italic toggle="yes">DDX41</italic> hot-spots, with &#x0201c;other&#x0201d; demonstrating patients with mutation other than p.M1|, p.Arg525His, p.Asp140GlyFs*2; (<bold>C</bold>) Kaplan&#x02013;Meier survival probability in p.M1| compared to p.Arg525His; (<bold>D</bold>) Kaplan&#x02013;Meier survival probability in p.M1| compared to p.Asp140GlyFs*2; (<bold>E</bold>) Kaplan&#x02013;Meier survival probability in p.Arg525His compared to p.Asp140GlyFs*2.</p></caption><graphic xlink:href="hematolrep-17-00026-g001" position="float"/></fig><table-wrap position="float" id="hematolrep-17-00026-t001"><object-id pub-id-type="pii">hematolrep-17-00026-t001_Table 1</object-id><label>Table 1</label><caption><p>General characteristics of 68 patients with <italic toggle="yes">DDX41</italic> mutation identified on NGS (next generation sequencing). N: number; MDS: myelodysplastic syndrome; AML; acute myeloid leukemia; MPN: myeloproliferative neoplasm; CCUS; clonal cytopenia of undetermined significance; CHIP: clonal hematopoiesis of indeterminate potential; VAF: variant allele frequency; BM: bone marrow.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Patients Identified to Have <italic toggle="yes">DDX41</italic> Mutation (N = 68)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median age, yrs (range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 (30&#x02013;93)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male sex, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (70%) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diagnosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDS, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (44%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AML, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (34%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPN, N (%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (6%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DDX41 carrier, N(%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCUS, N (%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (6%) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIP, N (%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1%) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abnormal cytogenetics, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 (29%) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median <italic toggle="yes">DDX41</italic> VAF % </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AML progression, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (16%) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Underwent BM transplantation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 (29%) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Confirmed germline mutation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (24%) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median BM blast% </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="hematolrep-17-00026-t002"><object-id pub-id-type="pii">hematolrep-17-00026-t002_Table 2</object-id><label>Table 2</label><caption><p>Characteristics and hematological features of mutated <italic toggle="yes">DDX41</italic>, with comparison between hot-spots p.M1|, p.Arg525His, and p.Asp140GlyFs*2. Cohort 1: p.M1|, Cohort 2: p.Arg525His, Cohort 3: p.Asp140GlyFs*2. N: number; MDS: myelodysplastic syndrome; AML; acute myeloid leukemia; MPN: myeloproliferative neoplasm; CCUS; clonal cytopenia of undetermined significance; VAF: variant allele frequency; BM: bone marrow.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1"><italic toggle="yes">DDX41</italic> p.M1|, <break/>N = 23</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1"><italic toggle="yes">DDX41</italic> p.Arg525His,<break/>N = 9</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1"><italic toggle="yes">DDX41</italic> p.Asp140GlyFs*2,<break/>N = 8</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Median age, yrs (range)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 (30&#x02013;83)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69 (59&#x02013;90)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63.5 (60&#x02013;82)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Male sex, N (%)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (65%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (78%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Diagnosis</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDS, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (39%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (56%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (88%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AML, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (26%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (22%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (12.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPN, N (%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (11%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">DDX41</italic> carrier, N(%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (13%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCUS, N (%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (13%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Mean number of co-mutations, (range)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3 (0&#x02013;2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6 (0&#x02013;2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5 (0&#x02013;2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.63</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Co-mutations</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">ASXL1</italic>, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (13%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (13%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.79</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">JAK2</italic>, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (11%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">DNMT3A</italic>, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (29%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">TP53</italic>, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">NRAS</italic>, N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.59</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Abnormal cytogenetics, N (%)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (33%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (25%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Median <italic toggle="yes">DDX41</italic> VAF % (range)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (15&#x02013;52)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (4&#x02013;24)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (37&#x02013;50)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>AML progression, N (%)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (5.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (25%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Labs</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median hemoglobin (g/dL) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.2 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.4 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median platelet (&#x000d7;10<sup>9</sup>/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">153</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.64</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median white blood count (&#x000d7;10<sup>9</sup>/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.8 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median BM blast % </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.57</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Overall survival (OS)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12-month OS (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86%</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cohort 1 vs. 2: 0.41<break/>Cohort 1 vs. 3: 0.79<break/>Cohort 2 vs. 3: 0.43</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24-month OS (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71%</td></tr></tbody></table></table-wrap></floats-group></article>